top of page
Search

Promethean BioPharma supports the rescheduling of psilocybin and MDMA in Australia

Updated: Mar 8, 2022

Promethean BioPharma supports the work of Mind Medicine Australia and encourages their submissions to the Therapeutic Goods Administration in relation to the rescheduling of psilocybin and MDMA from Schedule 9 to Schedule 8.


For more information:

https://mindmedicineaustralia.org.au/


https://mindmedicineaustralia.org.au/wp-content/uploads/Mind-Medicine-Australia-Invitation-for-Rescheduling-Guide-27-August-2020.pdf


https://mindmedicineaustralia.org.au/wp-content/uploads/Mind-Medicine-Australia-Fact-Sheet-22-February-2021.pdf


Recent Posts

See All

Promethean BioPharma Limited has finalised the acquisition of Tcann Pty Ltd setting the stage for the execution of it's growth strategy.

bottom of page